PT-141 (known generically as bremelanotide and sold under the brand name Vyleesi) is a synthetic peptide that activates melanocortin receptors (primarily MC4R) in the central nervous system. Unlike traditional erectile dysfunction drugs like sildenafil (Viagra) or tadalafil (Cialis)—which work peripherally on blood vessels to help with the mechanical process of an erection—PT-141 acts directly on brain pathways that regulate sexual motivation, desire, and arousal.

Main Benefits

• Increased Sexual Desire (Libido): PT-141 is clinically shown to boost subjective sexual desire and reduce distress related to low libido.

• Enhanced Arousal: It promotes physiological and subjective sexual arousal in both central brain signaling and genital response pathways. 

• Central (Non-Vascular) Mechanism: Because it triggers desire and arousal in the brain rather than relying purely on peripheral blood flow, it can sometimes help individuals (including some men) who do not respond well to PDE5 inhibitors like Viagra.

• Longer Window of Effect: Depending on the dosage and individual metabolism, the effects of PT-141 can last anywhere from several hours up to 24–48+ hours (with onset typically occurring 30 to 60 minutes to a few hours after administration). 

Regulatory Status & Evidence

• FDA Approval (Women): Bremelanotide is FDA-approved as an injectable medication (Vyleesi) specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) that is not caused by underlying medical, mental health, or relationship issues

• Use in Men: While widely discussed, researched, and prescribed off-label or through specialized men's health/peptide clinics for male sexual dysfunction and low libido, PT-141 is not FDA-approved for men.